MIAMI, Aug. 20, 2025 — Leads & Copy — Longeveron Inc. (NASDAQ: LGVN) will participate in the H.C. Wainwright 27th Annual Global Investment Conference on Sept. 8-10, 2025, in New York City. The presentation is scheduled for Monday, September 8, 2025, from 4:00 – 4:30 p.m. ET.
The webcast can be accessed in the “Events and Presentations” section of the company’s website, with a replay available for 180 days following the conference.
Longeveron is a clinical stage biotechnology company developing regenerative medicines. Its lead product, laromestrocel (Lomecel-B™), is an allogeneic mesenchymal stem cell therapy with potential applications across disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel programs have received FDA designations for the HLHS and AD programs.
Derek Cole, Investor Relations Advisory Solutions, derek.cole@iradvisory.com
Source: Longeveron Inc.
